Marzena Walkiewicz

905 total citations
31 papers, 674 citations indexed

About

Marzena Walkiewicz is a scholar working on Molecular Biology, Pulmonary and Respiratory Medicine and Oncology. According to data from OpenAlex, Marzena Walkiewicz has authored 31 papers receiving a total of 674 indexed citations (citations by other indexed papers that have themselves been cited), including 14 papers in Molecular Biology, 12 papers in Pulmonary and Respiratory Medicine and 11 papers in Oncology. Recurrent topics in Marzena Walkiewicz's work include Occupational and environmental lung diseases (8 papers), Cancer Research and Treatments (6 papers) and Cancer Immunotherapy and Biomarkers (6 papers). Marzena Walkiewicz is often cited by papers focused on Occupational and environmental lung diseases (8 papers), Cancer Research and Treatments (6 papers) and Cancer Immunotherapy and Biomarkers (6 papers). Marzena Walkiewicz collaborates with scholars based in Australia, Canada and United States. Marzena Walkiewicz's co-authors include Thomas John, Simon Knight, Stephen Barnett, Gavin Wright, Carmel Murone, Paul C. Boutros, Jonathan Cebon, Prudence A. Russell, Bibhusal Thapa and Xihui Lin and has published in prestigious journals such as Journal of Clinical Oncology, PLoS ONE and Scientific Reports.

In The Last Decade

Marzena Walkiewicz

31 papers receiving 667 citations

Peers

Marzena Walkiewicz
Silvia Fenoglio United States
Yanqing Wang United States
Stefanie Kurtz Switzerland
Jeffery J. Raizer United States
Gonzalo Torga United States
Judy S. Wang United States
Vicki L. Hopwood United States
Silvia Fenoglio United States
Marzena Walkiewicz
Citations per year, relative to Marzena Walkiewicz Marzena Walkiewicz (= 1×) peers Silvia Fenoglio

Countries citing papers authored by Marzena Walkiewicz

Since Specialization
Citations

This map shows the geographic impact of Marzena Walkiewicz's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Marzena Walkiewicz with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Marzena Walkiewicz more than expected).

Fields of papers citing papers by Marzena Walkiewicz

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Marzena Walkiewicz. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Marzena Walkiewicz. The network helps show where Marzena Walkiewicz may publish in the future.

Co-authorship network of co-authors of Marzena Walkiewicz

This figure shows the co-authorship network connecting the top 25 collaborators of Marzena Walkiewicz. A scholar is included among the top collaborators of Marzena Walkiewicz based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Marzena Walkiewicz. Marzena Walkiewicz is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Helman, Guy, Marzena Walkiewicz, Stefanie Eggers, et al.. (2021). Aberrant splicing and transcriptional activity of TPP1 result in CLN2-like disorder. European Journal of Medical Genetics. 64(8). 104259–104259. 2 indexed citations
2.
Deléage, Claire, Candani Tutuka, Marzena Walkiewicz, et al.. (2021). Multiparameter immunohistochemistry analysis of HIV DNA, RNA and immune checkpoints in lymph node tissue. Journal of Immunological Methods. 501. 113198–113198. 5 indexed citations
3.
Arulananda, Surein, Megan A. O’Brien, Marco Evangelista, et al.. (2021). A novel BH3-mimetic, AZD0466, targeting BCL-XL and BCL-2 is effective in pre-clinical models of malignant pleural mesothelioma. Cell Death Discovery. 7(1). 122–122. 30 indexed citations
4.
Prithviraj, Prashanth, Matthew Anaka, Erik W. Thompson, et al.. (2020). Aberrant pregnancy-associated plasma protein-A expression in breast cancers prognosticates clinical outcomes. Scientific Reports. 10(1). 13779–13779. 7 indexed citations
5.
Chia, Puey Ling, Sagun Parakh, Prudence A. Russell, et al.. (2020). Expression of EGFR and conformational forms of EGFR in malignant pleural mesothelioma and its impact on survival. Lung Cancer. 153. 35–41. 11 indexed citations
6.
Chia, Puey Ling, Prudence A. Russell, Bibhusal Thapa, et al.. (2020). Analysis of angiogenic and stromal biomarkers in a large malignant mesothelioma cohort. Lung Cancer. 150. 1–8. 10 indexed citations
7.
Arulananda, Surein, Megan A. O’Brien, Marco Evangelista, et al.. (2020). BCL-XL is an actionable target for treatment of malignant pleural mesothelioma. Cell Death Discovery. 6(1). 114–114. 16 indexed citations
8.
Helman, Guy, Alison G. Compton, Daniella H. Hock, et al.. (2020). Multiomic analysis elucidates Complex I deficiency caused by a deep intronic variant in NDUFB10. Human Mutation. 42(1). 19–24. 18 indexed citations
9.
Rivalland, Gareth, Paul Mitchell, Carmel Murone, et al.. (2019). Mesenchyme to epithelial transition protein expression, gene copy number and clinical outcome in a large non-small cell lung cancer surgical cohort. Translational Lung Cancer Research. 8(2). 167–175. 6 indexed citations
10.
Arulananda, Surein, Bibhusal Thapa, Marzena Walkiewicz, et al.. (2018). Mismatch Repair Protein Defects and Microsatellite Instability in Malignant Pleural Mesothelioma. Journal of Thoracic Oncology. 13(10). 1588–1594. 34 indexed citations
11.
Prithviraj, Prashanth, et al.. (2017). PAPP-A is a marker of aggressive breast cancer and promotes cancer progression in-vitro. Annals of Oncology. 28. x170–x171. 1 indexed citations
12.
Thapa, Bibhusal, Adriana Salcedo, Xihui Lin, et al.. (2017). The Immune Microenvironment, Genome-wide Copy Number Aberrations, and Survival in Mesothelioma. Journal of Thoracic Oncology. 12(5). 850–859. 73 indexed citations
13.
Thapa, Bibhusal, Marzena Walkiewicz, Gareth Rivalland, et al.. (2017). Immune microenvironment in mesothelioma: Looking beyond PD-L1.. Journal of Clinical Oncology. 35(15_suppl). 8515–8515. 5 indexed citations
14.
Thapa, Bibhusal, Marzena Walkiewicz, Carmel Murone, et al.. (2016). Calretinin but not caveolin-1 correlates with tumour histology and survival in malignant mesothelioma. Pathology. 48(7). 660–665. 15 indexed citations
15.
Ameratunga, Malaka, Xihui Lin, Marzena Walkiewicz, et al.. (2016). PD-L1 and Tumor Infiltrating Lymphocytes as Prognostic Markers in Resected NSCLC. PLoS ONE. 11(4). e0153954–e0153954. 67 indexed citations
16.
Jayachandran, Aparna, Anderly C. Chüeh, Prashanth Prithviraj, et al.. (2016). Transketolase-like 1 ectopic expression is associated with DNA hypomethylation and induces the Warburg effect in melanoma cells. BMC Cancer. 16(1). 134–134. 28 indexed citations
17.
Rivalland, Gareth, Malaka Ameratunga, Marzena Walkiewicz, et al.. (2016). Programmed Death–Ligand 1 (PD-L1) immumohistochemistry in NSCLC: Comparison and correlation between two antibodies.. Journal of Clinical Oncology. 34(15_suppl). e20036–e20036. 3 indexed citations
18.
Ameratunga, Malaka, et al.. (2015). Prognostic significance of stromal versus intratumoral infiltrating CD8+ lymphocytes in resected non-small cell lung cancer.. Journal of Clinical Oncology. 33(15_suppl). 11051–11051. 1 indexed citations
19.
Russell, Prudence A., Stephen Barnett, Marzena Walkiewicz, et al.. (2013). Correlation of Mutation Status and Survival with Predominant Histologic Subtype According to the New IASLC/ATS/ERS Lung Adenocarcinoma Classification in Stage III (N2) Patients. Journal of Thoracic Oncology. 8(4). 461–468. 97 indexed citations
20.
John, Thomas, Maud H. W. Starmans, Yao‐Tseng Chen, et al.. (2013). The Role of Cancer-Testis Antigens as Predictive and Prognostic Markers in Non-Small Cell Lung Cancer. PLoS ONE. 8(7). e67876–e67876. 38 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026